GTBP GT Biopharma Corp: רווח נקי למניה אחת בשנים עשר החודשים האחרונים

In the immuno-oncology sector, GT Biopharma, Inc. (GTBP) faces fierce competition and regulatory pressure. The EPS YoY TTM percentage trend demonstrates current earnings resilience, with the current value equal to 74.60. The company is implementing the TriKE platform for NK-cell activation, bypassing costly CAR-T. Drug selection efficiency is increasing through automated protein modeling and robotic testing.
פילוחי מדדים פיננסיים ומדדי שוק עבור GT Biopharma Corp (GTBP)

Selecting assets with a high margin of safety begins with an analysis of profit dynamics. This indicator captures the annual growth rate of rolling net earnings per share, reflecting the market consensus regarding business efficiency. For GT Biopharma, Inc. (GTBP), which is developing innovative TriKE drugs, this metric measures the monetization speed of its oncological developments. By analyzing the year-over-year EPS history (TTM), an investor determines the company's readiness for scaling.